Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors. Ypsomed is ...

Sept 20 (Reuters) - Swiss medical technology company Ypsomed YPSN.S announced on Wednesday a long-term supply deal with Novo Nordisk NOVOb.CO for autoinjectors, the latest sign of how the Danish ...

The Swiss diabetes hardware company Ypsomed is selling off its insulin pen needle and blood sugar monitoring operations, as it turns its attention toward its drug autoinjectors and digital insulin ...

Lannett has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its biosimilar insulin glargine and biosimilar insulin ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business with a plan to trade its insulin pump development arm and remaining ...

Earnings call Ypsomed reported CHF 267M in core delivery systems revenue for H1 FY25/26, growing 21% YoY, with EBIT of CHF 87M and a 32.4% margin. Management reaffirmed FY guidance for ~20% revenue ...